Adrenoleukodystrophy unravelled

July 30, 2012
Adrenoleukodystrophy unravelled
Credit: Thinkstock

The European X-ALD project undertook an initiative to understand the mechanisms responsible for the pathogenesis of adrenoleukodystrophy (ALD). The gene therapy approach for treating ALD developed during the study brings hope to many young boys that have inherited the disease.

ALD is a progressive metabolic that occurs approximately in 1 in 17,000 newborns. It is caused by mutations in the ABCD1 gene located on the and affects the of the . Biochemically, X-linked ALD (X-ALD) is characterised by transport deficiency of very long-chain fatty acids (VLCFAs).

Accumulating evidence suggests that the ABCD1 gene codes for a protein that is probably implicated in the transport of VLCFAs into a specific intracellular organelle, called the . To this end, a model based on the yeast S. cerevisae has been developed to study the function of ALD protein.

Using this model, the EU-funded ‘X-linked Adrenoleukodystrophy (X-ALD): pathogenesis, animal models and therapy’ (X-ALD) project aimed to prove the role of ALD protein in VLCFA transport. Expression of ALD protein in genetically engineered yeast cells was capable of restoring the defective transport of VLCFAs. In vitro experiments using mammalian peroxisomes verified the yeast findings, conclusively demonstrating for the first time the function of the ALD protein.

Furthermore, project scientists developed new X-ALD mouse models which helped them identify candidates for modifier genes that could account for the phenotypic variability seen in ALD patients. The substantial progress made towards the understanding of the pathogenic mechanisms underlying the disease has aided the development of novel therapeutic approaches and the first clinical application of gene therapy in X-ALD.

The X-ALD work carried out in this project is expected to have significant implications with regards to future therapeutic treatment of X-ALD patients.

Explore further: VESTA and IPS Enter into Exclusive Agreement to Supply Atomic Layer Deposition Technology and Solution

Related Stories

Gene therapy technique slows ALD brain disease

November 5, 2009

A strategy that combines gene therapy with blood stem cell therapy may be a useful tool for treating a fatal brain disease, French researchers have found. These findings appear in the 6 November 2009 issue of the journal ...

Genes modify the risk of liver disease among alcoholics

December 6, 2011

It has been widely observed that only a small percentage of alcoholics develop cirrhosis of the liver, the most advanced form of alcoholic liver disease (ALD); the reason why all alcoholics do not develop such disease is ...

Recommended for you

Face shape is in the genes

August 25, 2016

Many of the characteristics that make up a person's face, such as nose size and face width, stem from specific genetic variations, reports John Shaffer of the University of Pittsburgh in Pennsylvania, and colleagues, in a ...

Researchers discover otulipenia, a new inflammatory disease

August 22, 2016

National Institutes of Health researchers have discovered a rare and sometimes lethal inflammatory disease - otulipenia - that primarily affects young children. They have also identified anti-inflammatory treatments that ...

Solving the mystery of meningiomas reveals a surprise twist

August 23, 2016

In solving one mystery—the genetic roots of benign brain tumors called meningiomas—a team of scientists led by Yale researchers stumbled upon an even greater one: How is it possible that two of the mutations linked to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.